Cara to seek strategic alternatives after difelikefalin trial failure in pruritus

seekingalpha06-13

Cara Therapeutics (NASDAQ:CARA) said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443597849?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196157315/image_1196157315.jpg","is_english":true,"pubTime":"2024-06-13 04:19","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2443597849","market":"sg","top_or_hot":-1,"title":"Cara to seek strategic alternatives after difelikefalin trial failure in pruritus","media":"seekingalpha","content":"<div>\n<p>Cara Therapeutics (NASDAQ:CARA) said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful ...</p>\n\n<a href=\"https://seekingalpha.com/news/4115351-cara-seek-strategic-alternatives-difelikefalin-trial-failure-pruritus\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cara to seek strategic alternatives after difelikefalin trial failure in pruritus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCara to seek strategic alternatives after difelikefalin trial failure in pruritus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4115351-cara-seek-strategic-alternatives-difelikefalin-trial-failure-pruritus><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cara Therapeutics (NASDAQ:CARA) said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful ...</p>\n\n<a href=\"https://seekingalpha.com/news/4115351-cara-seek-strategic-alternatives-difelikefalin-trial-failure-pruritus\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4115351-cara-seek-strategic-alternatives-difelikefalin-trial-failure-pruritus","article_id":"2443597849","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196157315/image_1196157315.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443597849","pubTimestamp":1718223571,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Cara Therapeutics  said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful clinical benefit at any dose versus placebo in the KOURAGE-1 Part A trial. As a result, the company will wind down the phase 2/3 program. The drug was under investigation for prurirus, also known as itching, associated with notalgia paresthetica.  As of March 31, Cara had $70M in cash, cash equivalents, and marketable securities.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CARA":"Cara Therapeutics, Inc."},"translate_title":"difelikefalin治疗瘙痒症试验失败后，Cara将寻求战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARA":1},"content_text":"Cara Therapeutics (NASDAQ:CARA) said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful clinical benefit at any dose versus placebo in the KOURAGE-1 Part A trial. As a result, the company will wind down the phase 2/3 program. The drug was under investigation for prurirus, also known as itching, associated with notalgia paresthetica.  As of March 31, Cara had $70M in cash, cash equivalents, and marketable securities.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443597849"}